Sentiment-Signal ⓘ
Score-Verlauf (90 Tage)
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner | Open Market Sale | -438 | 18,00 | -7.884,00 | -0,2% | |
| 2026-05-11 | SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner | Open Market Sale | -1.065 | 18,00 | -19.170,00 | -0,4% | |
| 2026-05-11 | Li Nan (LN) | Director | Open Market Purchase | 1.111.111 | 18,00 | 19.999.998,00 | +436,9% | |
| 2026-05-11 | Chu Shelley | Director | Open Market Purchase | 11.111 | 18,00 | 199.998,00 | +4,4% | |
| 2026-05-11 | SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner | Open Market Purchase | 133.333 | 18,00 | 2.399.994,00 | +52,4% | |
| 2026-05-11 | SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner | Open Market Purchase | 200.000 | 18,00 | 3.600.000,00 | +78,6% | |
| 2026-05-11 | SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner | Open Market Purchase | 222.222 | 18,00 | 3.999.996,00 | +87,4% | |
| 2026-05-11 | SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner | Open Market Sale | -277 | 18,00 | -4.986,00 | -0,1% | |
| 2026-05-08 | Dimension Capital II, L.P. | Director | Open Market Purchase | 1.111.111 | 18,00 | 19.999.998,00 | +436,9% | |
| 2026-05-08 | Haas Jason | Officer, Chief Financial Officer | Open Market Purchase | 1.000 | 20,00 | 20.000,00 | +0,4% | |
| 2026-05-08 | LEIDEN JEFFREY M | Director | Open Market Purchase | 5.000 | 20,00 | 100.000,00 | +2,2% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.
Stammdaten
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptorassociated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5. The company was incorporated in 2021 and is headquartered in Boston, Massachusetts.
Unternehmen & Branche
| Name | Odyssey Therapeutics, Inc. |
|---|---|
| Ticker | ODTX |
| CIK | 0001882782 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 514,6 Mio. USD |
| Beta | 0,00 |
| Dividendenrendite | 0,00 % |
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance »